Pei Liu

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Fengcai Zhu, Fanyue Meng, Jingxin Li et al. · The Lancet · 2013 · 382 citations

Vaccination, Vaccine Safety, Vaccine Development +5

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Fengcai Zhu, Lihua Hou, Jingxin Li et al. · The Lancet · 2015 · 187 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

Jingxin Li, Lihua Hou, Fanyue Meng et al. · The Lancet Global Health · 2016 · 101 citations · Full text

Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial

Fengcai Zhu, Zhenglun Liang, Xiuling Li et al. · The Lancet · 2013 · 87 citations

Vaccination, Vaccine Safety, Placebo-controlled Phase 2 +7

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Lihua Wu, Zhe Zhang, Hainv Gao et al. · Human Vaccines & Immunotherapeutics · 2017 · 36 citations · Full text